JYB 1904
Alternative Names: Anti-immunoglobulin E antibody - Jemincare; JYB-1904Latest Information Update: 25 Jul 2024
At a glance
- Originator Jemincare
- Class Antiasthmatics; Antibodies; Biobetters
- Mechanism of Action Immunoglobulin E inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Allergic asthma
- Phase I Asthma
Most Recent Events
- 19 Jul 2024 Jemincare plans a phase II trial for Chronic-urticaria (Treatment-experienced) in China (SC, injection) in July 2024 (NCT06509334)
- 19 Jun 2024 Phase-II clinical trials in Allergic asthma in China (SC) (NCT06438757)
- 04 Jun 2024 Jemincare plans a phase IIa trial for Allergic asthma in China in June 2024 (NCT06438757)